Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/9/2018 |
| Start Date: | December 2016 |
| End Date: | June 2020 |
| Contact: | Karlyn Pierson, RN |
| Email: | pierson.karlyn@mayo.edu |
| Phone: | 507-538-1960 |
The purpose of this study is to explore the detection of circulating tumor DNA, soluble
immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
Our plan is to collect blood from patients with advanced stage lung cancer who are scheduled
to undergo systemic therapy. In this study we will utilize a novel technology for circulating
tumor DNA detection in order to evaluate their presence in patients with lung cancer by
comparing blood samples at six time points. We will obtain baseline blood and then collect
blood at five time points during the course of the patient's chemotherapy treatments and at
the end of treatment. These same blood collections will be used for the detection of soluble
immune markers and evaluation of PBMCs.
to undergo systemic therapy. In this study we will utilize a novel technology for circulating
tumor DNA detection in order to evaluate their presence in patients with lung cancer by
comparing blood samples at six time points. We will obtain baseline blood and then collect
blood at five time points during the course of the patient's chemotherapy treatments and at
the end of treatment. These same blood collections will be used for the detection of soluble
immune markers and evaluation of PBMCs.
Inclusion Criteria:
- Advanced (non-resectable) malignancy in the thorax
- Age >18 years old
- Willing and able to provide consent
- No prior history of neoadjuvant therapy
Exclusion Criteria:
- Age <18 years old
- Unable to provide consent
- Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential
iatrogenic anemia)
We found this trial at
1
site
Rochester, Minnesota 55905
Principal Investigator: Aaron Mansfield, MD
Phone: 507-538-1960
Click here to add this to my saved trials
